merck is widely tipped to come out on top with it's results tomorrow re nsclc at ACA....
interesting to us is the mooted trial in the US for keytruda and efti alpha in a
supply collaboration with Immutep......presumably merck had discussions with
Immutep about which direction to proceed in these collaborations.....
Add to My Watchlist
What is My Watchlist?